Testosterone
Eur Neurol. 1985;24(1):53-6.
Use of testosterone in the treatment of cluster headache.
Klimek A
The study was carried out on 15 men suffering from the episodic form (12
patients) and the chronic one (3 patients) of cluster headache. Before treatment
the patients did not receive any drugs, and after determining the index of
attacks the treatment was commenced. For 7-10 days patients were given
testosteronum propionicum (25 mg) once a day intramuscularly, and then for the
same period of time testosterone (10 mg). Before treatment the index of attacks
was 3.66 (total number of attacks 308). In the 1st week of treatment the index
decreased to 1.11 (total number of attacks 94) and to 0.16 in the 2nd week. In 3
patients with the chronic form of cluster headache testosterone was ineffective.
PMID: 3967676
Headache. 2006 Jun;46(6):925-33.
Testosterone replacement therapy for treatment refractory cluster headache.
Stillman MJ.
Objectives.-To describe the clinical characteristics and laboratory findings of
cluster headache patients whose headaches responded to testosterone replacement
therapy. Background.-Current evidence points to hypothalamic dysfunction, with
increased metabolic hyperactivity in the region of the suprachiasmatic nucleus,
as being important in the genesis of cluster headaches. This is clinically borne
out in the circadian and diurnal behavior of these headaches. For years it has
been recognized that male cluster headache patients appear overmasculinized.
Recent neuroendocrine and sleep studies now point to an association between
gonadotropin and corticotropin levels and hypothalamically entrained pineal
secretion of melatonin. Results.-Seven male and 2 female patients, seen between
July 2004 and February 2005, and between the ages of 32 and 56, are reported
with histories of treatment resistant cluster headaches accompanied by
borderline low or low serum testosterone levels. The patients failed to respond
to individually tailored medical regimens, including melatonin doses of 12 mg a
day or higher, high flow oxygen, maximally tolerated verapamil, antiepileptic
agents, and parenteral serotonin agonists. Seven of the 9 patients met 2004
International Classification for the Diagnosis of Headache criteria for chronic
cluster headaches; the other 2 patients had episodic cluster headaches of
several months duration. After neurological and physical examination all
patients had laboratory investigations including fasting lipid panel, PSA (where
indicated), LH, FSH, and testosterone levels (both free and total). All 9
patients demonstrated either abnormally low or low, normal testosterone levels.
After supplementation with either pure testosterone in 5 of 7 male patients or
combination testosterone/estrogen therapy in both female patients, the patients
achieved cluster headache freedom for the first 24 hours. Four male chronic
cluster patients, all with abnormally low testosterone levels, achieved
remission. Conclusions.-Abnormal testosterone levels in patients with episodic
or chronic cluster headaches refractory to maximal medical management may
predict a therapeutic response to testosterone replacement therapy. In the
described cases, diurnal variation of attacks, a seasonal cluster pattern, and
previous, transient responsiveness to melatonin therapy pointed to the
hypothalamus as the site of neurological dysfunction. Prospective studies
pairing hormone levels and polysomnographic data are needed.
PMID: 16732838
Page Last Updated: 06/08/2006